PeriodontitisNCT07574840
Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis
A study testing Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis in people with Periodontitis, run by The First Affiliated Hospital of Xinxiang Medical College.
Trial summary
The overall objective of this study is to evaluate the safety and efficacy of allogeneic human dental pulp stem cells (DPSCs) injected for the treatment of chronic periodontitis in humans. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Periodontitis
- What is being tested?
- Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 15 Apr 2026to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Disease Diagnosis: Clinically diagnosed with chronic periodontitis (typically Stage III or IV according to the latest periodontal disease classification).
- Target Tooth Requirements: At least two non-adjacent periodontal pockets with a Probing Pocket Depth (PPD) ≥5 mm.
- Clinical Attachment Level (CAL) loss ≥3 mm.
- Evidence of significant alveolar bone resorption on X-ray or CBCT (bone loss exceeding one-third of the root length).
- Age and General Condition: Typically aged 18-70 years, in good general health, and able to complete the 12-month follow-up.
- Oral Hygiene Awareness: Subjects are willing to receive conventional periodontal basic treatment (SRP) and demonstrate a good willingness to maintain oral hygiene (e.g., plaque index controlled at a low level).
Who cannot join
- Systemic Diseases: Presence of severe, uncontrolled systemic diseases (e.g., diabetes with HbA1c >7%, active hepatitis, tuberculosis). History of malignancy or immunodeficiency diseases (due to the proliferative potential of stem cells, cancer risk must be strictly excluded).
- Local Interfering Factors: Target teeth with severe mobility (Grade III mobility) or non-restorable residual crowns/roots. Received periodontal surgical treatment or systemic antibiotics within the past 3 months.
- Special Populations and Habits: Heavy smokers (typically defined as smoking >10 cigarettes per day), as smoking significantly inhibits the regenerative effect of stem cells and local blood supply. Pregnant or breastfeeding women. Individuals allergic to any components of the study preparation (e.g., specific biological carriers).
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Clinical Study of Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis
The overall objective of this study is to evaluate the safety and efficacy of allogeneic human dental pulp stem cells (DPSCs) injected for the treatment of chronic periodontitis in humans. It aims to develop a stem cell injection therapy that promotes the regeneration of periodontal soft and hard tissues through a non-invasive (minimally invasive) procedure, thereby replacing traditional traumatic periodontal surgery.
Read the detailed description
Periodontitis, a chronic inflammatory disease, affects over 700 million people worldwide, leading to bone and soft tissue destruction as well as systemic inflammatory manifestations. For severe periodontitis, current treatments mainly rely on invasive surgical procedures such as guided tissue regeneration, combined with bone grafting and growth factors. However, such surgeries often cause significant pain and discomfort to patients, and tissue regeneration is frequently incomplete, with risks of infection and uncontrolled tissue growth.
As a type of mesenchymal stem cell, dental pulp stem cells (DPSCs) can be easily obtained through a non-invasive procedure from orthodontically extracted or removed wisdom teeth. Compared to bone marrow- or adipose-derived stem cells, DPSCs exhibit stronger proliferative capacity and are better able to resist oxidative stress and cellular senescence within the periodontitis microenvironment. DPSCs have low immunogenicity and can interact with T cells, B cells, natural killer cells, macrophages, and others. For example, they can induce T cell anergy by secreting relevant factors, or regulate the proliferation and differentiation of B cells, thereby reducing the risk of immune rejection after allogeneic transplantation.
In light of the above research status, the conduct of this study holds the following outstanding value at both the scientific exploration and clinical application levels: Currently, most studies on stem cell therapy for periodontitis still rely on traditional flap surgery for transplantation. The DPSC injection therapy focused on in this study pioneeringly achieves the promotion of periodontal soft and hard tissue regeneration through simple local injection (e.g., intra-periodontal pocket injection). This not only greatly improves patient comfort but also provides a more convenient and minimally invasive treatment option for patients with severe periodontitis who would otherwise require complex periodontal surgery. The pathogenic mechanism of periodontitis is complex, with the core being the disruption of local microenvironmental homeostasis. Exogenous DPSC injection not only acts as "seed cells" for tissue regeneration but also, through paracrine secretion of various cytokines, remodels the immune microenvironment, restores local homeostasis, and thus achieves the "dual benefit" of reducing periodontal pocket depth and repairing alveolar bone defects. Investigating its specific molecular targets and regulatory pathways holds high scientific value. Considering that DPSCs are abundantly available, easily scalable for expansion, and have extremely low immunogenicity, they possess great potential as "off-the-shelf" allogeneic stem cell drugs. Compared to maxillofacial tissue reconstruction surgeries using recombinant growth factors, the minimally invasive stem cell injection strategy not only has a lower technical barrier but also offers significant advantages in time cost and economic efficiency, effectively reducing the healthcare burden.
- Conditions
- Periodontitis
- Being tested
- Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis
- Keywords
- Periodontitis, Dental pulp stem cells
- Medical subject headings
- Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Allogeneic Dental Pulp Stem Cells for the Treatment of PeriodontitisOther
The overall objective of this study is to evaluate the safety and efficacy of allogeneic human dental pulp stem cells (DPSCs) injected for the treatment of chronic periodontitis in humans. It aims to develop a stem cell injection therapy that promotes the regeneration of periodontal soft and hard tissues through a non-invasive (minimally invasive) procedure, thereby replacing traditional traumatic periodontal surgery.
| Study group | Role | What they receive |
|---|---|---|
| Allogeneic Dental Pulp Stem Cells | Experimental | Not described Receives: Other: Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Probing Pocket Depth (PPD)
The distance from the bottom of the periodontal pocket to the gingival margin is measured using a standardized periodontal probe.
Measured: Up to 12 month
Secondary outcomes (1)
Alveolar Bone Regeneration Height (Alveolar Bone Level):
Cone beam computed tomography (CBCT) scanning is used to quantitatively calculate the increase in bone height and changes in bone density in the vertical bone resorption area.
Measured: Up to 12 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2026
- Study start15 Apr 2026 (estimated)
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The First Affiliated Hospital of Xinxiang Medical College
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Wenjie Ren, Principal investigator, The First Affiliated Hospital of Xinxiang Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07574840
- Sponsor's protocol ID
- ADPSC-2026-01
- Status last verified
- May 2026
- First submitted
- 9 Apr 2026
- Last updated
- 8 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study of Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis
- ClinicalTrials.gov ID
- NCT07574840
- Acronym / sponsor ID
- ADPSC-2026-01
- Conditions
- Periodontitis
- Keywords
- Periodontitis, Dental pulp stem cells
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- The First Affiliated Hospital of Xinxiang Medical CollegeUniversity, hospital or other
- Study start
- 15 Apr 2026 (estimated)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 8 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall objective of this study is to evaluate the safety and efficacy of allogeneic human dental pulp stem cells (DPSCs) injected for the treatment of chronic periodontitis in humans. It aims to develop a stem cell injection therapy that promotes the regeneration of periodontal soft and hard tissues through a non-invasive (minimally invasive) procedure, thereby replacing traditional traumatic periodontal surgery.
Detailed description
Periodontitis, a chronic inflammatory disease, affects over 700 million people worldwide, leading to bone and soft tissue destruction as well as systemic inflammatory manifestations. For severe periodontitis, current treatments mainly rely on invasive surgical procedures such as guided tissue regeneration, combined with bone grafting and growth factors. However, such surgeries often cause significant pain and discomfort to patients, and tissue regeneration is frequently incomplete, with risks of infection and uncontrolled tissue growth.
As a type of mesenchymal stem cell, dental pulp stem cells (DPSCs) can be easily obtained through a non-invasive procedure from orthodontically extracted or removed wisdom teeth. Compared to bone marrow- or adipose-derived stem cells, DPSCs exhibit stronger proliferative capacity and are better able to resist oxidative stress and cellular senescence within the periodontitis microenvironment. DPSCs have low immunogenicity and can interact with T cells, B cells, natural killer cells, macrophages, and others. For example, they can induce T cell anergy by secreting relevant factors, or regulate the proliferation and differentiation of B cells, thereby reducing the risk of immune rejection after allogeneic transplantation.
In light of the above research status, the conduct of this study holds the following outstanding value at both the scientific exploration and clinical application levels: Currently, most studies on stem cell therapy for periodontitis still rely on traditional flap surgery for transplantation. The DPSC injection therapy focused on in this study pioneeringly achieves the promotion of periodontal soft and hard tissue regeneration through simple local injection (e.g., intra-periodontal pocket injection). This not only greatly improves patient comfort but also provides a more convenient and minimally invasive treatment option for patients with severe periodontitis who would otherwise require complex periodontal surgery. The pathogenic mechanism of periodontitis is complex, with the core being the disruption of local microenvironmental homeostasis. Exogenous DPSC injection not only acts as "seed cells" for tissue regeneration but also, through paracrine secretion of various cytokines, remodels the immune microenvironment, restores local homeostasis, and thus achieves the "dual benefit" of reducing periodontal pocket depth and repairing alveolar bone defects. Investigating its specific molecular targets and regulatory pathways holds high scientific value. Considering that DPSCs are abundantly available, easily scalable for expansion, and have extremely low immunogenicity, they possess great potential as "off-the-shelf" allogeneic stem cell drugs. Compared to maxillofacial tissue reconstruction surgeries using recombinant growth factors, the minimally invasive stem cell injection strategy not only has a lower technical barrier but also offers significant advantages in time cost and economic efficiency, effectively reducing the healthcare burden.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Allogeneic Dental Pulp Stem Cells | Experimental | Other: Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Disease Diagnosis: Clinically diagnosed with chronic periodontitis (typically Stage III or IV according to the latest periodontal disease classification).
- Target Tooth Requirements: At least two non-adjacent periodontal pockets with a Probing Pocket Depth (PPD) ≥5 mm.
- Clinical Attachment Level (CAL) loss ≥3 mm.
- Evidence of significant alveolar bone resorption on X-ray or CBCT (bone loss exceeding one-third of the root length).
- Age and General Condition: Typically aged 18-70 years, in good general health, and able to complete the 12-month follow-up.
Key exclusion criteria (3 listed)
- Systemic Diseases: Presence of severe, uncontrolled systemic diseases (e.g., diabetes with HbA1c >7%, active hepatitis, tuberculosis). History of malignancy or immunodeficiency diseases (due to the proliferative potential of stem cells, cancer risk must be strictly excluded).
- Local Interfering Factors: Target teeth with severe mobility (Grade III mobility) or non-restorable residual crowns/roots. Received periodontal surgical treatment or systemic antibiotics within the past 3 months.
- Special Populations and Habits: Heavy smokers (typically defined as smoking >10 cigarettes per day), as smoking significantly inhibits the regenerative effect of stem cells and local blood supply. Pregnant or breastfeeding women. Individuals allergic to any components of the study preparation (e.g., specific biological carriers).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Allogeneic Dental Pulp Stem Cells for the Treatment of PeriodontitisThe overall objective of this study is to evaluate the safety and efficacy of allogeneic human dental pulp stem cells (DPSCs) injected for the treatment of chronic periodontitis in humans. It aims to develop a stem cell injection therapy that promotes the regeneration of periodontal soft and hard tissues through a non-invasive (minimally invasive) procedure, thereby replacing traditional traumatic periodontal surgery. | Other | Allogeneic Dental Pulp Stem Cells |
Primary outcome
Change in Probing Pocket Depth (PPD)
Time frame: Up to 12 month
The distance from the bottom of the periodontal pocket to the gingival margin is measured using a standardized periodontal probe.
1 secondary outcome
Alveolar Bone Regeneration Height (Alveolar Bone Level):
Time frame: Up to 12 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
Related trials for Periodontitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Probiotics Versus Antibiotics as an Adjuvant to Non-surgical Periodontal Treatment Among Smokers With Stage II, Grade B Periodontitis
Probiotics, Antibiotics
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Wenjie Ren principal investigator
The First Affiliated Hospital of Xinxiang Medical College
Questions about this trial
What is this clinical trial studying?
A study testing Allogeneic Dental Pulp Stem Cells for the Treatment of Periodontitis in people with Periodontitis, run by The First Affiliated Hospital of Xinxiang Medical College.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wenjie Ren (8613937354075, 13937354075@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Probing Pocket Depth (PPD) (time frame: Up to 12 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.